scPharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
19/03/2025 21:01
scPharmaceuticals Inc SCPH.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended December 31, identical to the same quarter last year. The mean expectation of six analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -49 cents to -26 cents per share. Revenue rose 99.3% to $12.15 million from a year ago; analysts expected $12.08 million. scPharmaceuticals Inc's reported EPS for the quarter was a loss of 35 cents. The company reported a quarterly loss of $18.85 million. scPharmaceuticals Inc shares had fallen by 13.8% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 0.4% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for scPharmaceuticals Inc is $17.00 This summary was machine generated from LSEG data March 19 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.38 | -0.35 | Beat |
| Sep. 30 2024 | -0.30 | -0.75 | Missed |
| Jun. 30 2024 | -0.41 | -0.44 | Missed |
| Mar. 31 2024 | -0.44 | -0.36 | Beat |